No question about it: Express Scripts, the country's largest pharmacy benefit manager, just took a big hit. Shares are down about 20% since some unmistakably pessimistic language filling a recent earnings release. But is this really a reason to jump ship? In this video, Motley Fool health-care analyst Brenton Flynn outlines a trio of trends that support the bull argument for Express Scripts longer term.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.